Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Unburdens Itself Of Brodalumab

This article was originally published in Scrip

Executive Summary

AstraZeneca plc has managed to offload the dermatology candidate brodalumab to Valeant Pharmaceuticals International Inc following Amgen's decision to pull out of a co-development deal earlier this year. Amgen made the move owing to potential side effect issues, with suicidal thoughts being linked to brodalumab administration during clinical development, despite evidence of efficacy.

Advertisement

Related Content

Key Clinical Data And Drug Approvals Expected In 2H 2016
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
More Valeant Humiliation: Will The Messiness Ever End?
Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk
AstraZeneca Hands LEO Dermatology Potential

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC029650

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel